Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Inclusion Criteria: * History of at least 1 gout flare prior to the Screening Visit * Meeting the American College of Rheumatology (ACR) 1977 preliminary criteria for the classification of acute arthritis of primary gout. * Presence of acute gout flare for no longer than 5 days. * Baseline pain intensity \> or = to 50 mm on the 0-100 mm VAS. * Contraindicated for, intolerant or unresponsive to NSAIDs, colchicine or both. Exclusion Criteria: * Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis. * Presence of severe renal function impairment * Contraindication to intramuscular injection * Known presence or suspicion of active or recurrent bacterial, fungal or viral infection at the time of enrollment * Evidence of active pulmonary disease * Live vaccinations within 3 months prior to the start of the study * Use of forbidden therapy Other protocol-defined inclusion/exclusion criteria applied